An Open Label, Phase III Clinical Trial (Immunobridging Study) of INAVAC (Vaksin Merah Putih - UA-SARS-CoV-2 (Vero Cell Inactivated)) in Healthy Population Aged 12 to 17 Years Old

Tahapan Penelitian : Complete
Sponsor:
Mitra Pelaksana:
PT Biotis Pharmaceutical Indonesia, Universitas Airlangga
No Registry
INA-Q9EC6OB
Tanggal Input Registry : 19-07-2024

01-01-2023
not specified
 
An Open Label, Phase III Clinical Trial (Immunobridging Study) of INAVAC (Vaksin Merah Putih - UA-SARS-CoV-2 (Vero Cell Inactivated)) in Healthy Population Aged 12 to 17 Years Old
An Open Label, Phase III Clinical Trial (Immunobridging Study) of INAVAC (Vaksin Merah Putih - UA-SARS-CoV-2 (Vero Cell Inactivated)) in Healthy Population Aged 12 to 17 Years Old
Interventional
INAVAC (Vaksin Merah Putih - UA-SARS-CoV-2 (Vero Cell Inactivated))
5
 

Inclusion Criteria:

not specified

Exclusion Criteria:

not specified
 
not specified
Not applicable
PPUK/PPUB number
not specified